Xenetic Biosciences Inc. and University of Virginia Team Up to Advance DNase-Based Oncology Platform: A Partnership for Progress!
Company continuing to advance DNase-based oncology program towards clinical proof-of-concept studies in multiple indications
FRAMINGHAM, MA / ACCESSWIRE / December 16, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO)
Xenetic Biosciences, Inc., a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat cancers, has announced an extension of its Research Funding Agreement with the University of Virginia (UVA) to further develop its systemic DNase program through 2025. This partnership represents a significant step forward in advancing the DNase-based oncology platform, which targets neutrophil extracellular traps (NETs).
NETs are web-like structures composed of extracellular chromatin coated with histones and other proteins. By focusing on targeting these structures, Xenetic’s DNase program aims to tackle hard-to-treat cancers by disrupting NET formation and preventing the spread of cancer cells.
This collaboration between Xenetic Biosciences and the University of Virginia marks a partnership for progress in the field of oncology research. By combining their expertise and resources, the two entities are pushing towards clinical proof-of-concept studies in multiple indications, potentially paving the way for innovative treatment options for patients battling cancer.
As the DNase-based oncology platform continues to advance, the potential for groundbreaking developments in cancer treatment looms on the horizon. With a focus on addressing challenges in cancer therapy through novel approaches, Xenetic Biosciences and UVA are at the forefront of driving innovation in the field of immuno-oncology.
How This Will Affect Me:
As a potential future patient, the collaboration between Xenetic Biosciences and the University of Virginia offers hope for more effective and targeted treatment options for cancer. The advancements in the DNase-based oncology platform could potentially lead to improved outcomes and better quality of life for individuals facing hard-to-treat cancers.
How This Will Affect the World:
The partnership between Xenetic Biosciences and the University of Virginia has the potential to have far-reaching implications in the world of oncology research and cancer treatment. By advancing innovative technologies and focusing on disrupting NET formation, this collaboration could pave the way for new treatment strategies that have the potential to impact cancer care on a global scale.
Conclusion:
The extension of the Research Funding Agreement between Xenetic Biosciences Inc. and the University of Virginia signifies a significant step forward in the advancement of DNase-based oncology research. This partnership represents a commitment to progress and innovation in the fight against cancer, with the potential to bring about transformative changes in cancer treatment practices. As the DNase program continues to develop, there is hope on the horizon for improved outcomes for patients battling cancer, making this collaboration a beacon of hope in the field of oncology.
